A carregar...
Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
LESSONS LEARNED. Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study. Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected. No efficacy conclusion c...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5469595/ https://ncbi.nlm.nih.gov/pubmed/28465370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0137 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|